Get started
Author

Jedelyn Cabrieto

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
2024 · Hermann Einsele, Philippe Moreau, et al. · Advances in Therapy · 20
PDF
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
2023 · Christos Chouaid, Lise Bosquet, et al. · Advances in Therapy · 18
PDF
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry
2021 · Maximilian Merz, Hartmut Goldschmidt, et al. · Cancers · 15
PDF
Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study
2021 · Maria-Victoria Mateos, Katja Weisel, et al. · Blood · 11
Diagnostic Accuracy of Imaging in Assessing Nonviability of Disappearing Colorectal Liver Metastasis
2025 · Kozo Kataoka, Murielle Mauer, et al. · JAMA Surgery · 10
PDF
P-050 Talquetamab vs Real-World Physician's Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent
2024 · María-Victoria Mateos Manteca, Andrzej Jakubowiak, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
EORTC1527/JCOG1609INT/ESSO002: DW-MRI Assessment of Disappearing Liver Metastasis to Improve Surgical Planning (DREAM)
2025 · K. Kataoka, S. Stättner, et al. · European Journal of Surgical Oncology · 1
Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear-cell Renal Cell Carcinoma: The Multicentre, Single-arm, Phase 2 RENALUT Trial
2025 · Emmanuel Seront, Mehdi Bsilat, et al. · European Urology Oncology · 1
Single-Agent Ibrutinib Versus Real-World (RW) Treatments for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Adjusted Comparison of Resonate-2™ with the Cllear and Lyon-Sud Rw Databases
2021 · Michael Doubek, Mudr. Lukas Smolej, et al. · Blood · 1
EORTC1527/JCOG1609INT/ESSO02: Diffusion-weighted magnetic resonance imaging (DW-MRI) assessment of initially unresectable liver metastasis to improve surgical planning (DREAM)—Primary analysis.
2025 · Kozo Kataoka, Murielle E. Mauer, et al. · Journal of Clinical Oncology
P-018 Updated Comparative Effectiveness of Talquetamab vs Real-World Physician's Choice of Treatment in LocoMMotion and MoMMent for Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
2024 · Hermann Einsele, Philippe Moreau, et al. · Clinical Lymphoma Myeloma & Leukemia
P-091 Talquetamab Versus Belgian Real-World Clinical Practice in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Patients Using Adjusted Comparison
2024 · Marie-Christiane Vekemans, Sébastien Anguille, et al. · Clinical Lymphoma Myeloma & Leukemia
P923: Comparative Effectiveness of Talquetamab Vs Real-world Physician’s Choice of Treatment in Locommotion and Momment for Patients With Triple-class Exposed Relapsed/refractory Multiple Myeloma
2023 · Hermann Einsele, Philippe Moreau, et al. · HemaSphere
CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
2022 · C Chouaid, N Girard, et al. · Value in Health
Works count: 14
Citation count: 79
H-index: 5
I10-index: 5
Year
Topic
Type